Literature DB >> 6338833

Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine.

S S Husain, V Gurewich, B Lipinski.   

Abstract

Affinity chromatography on fibrin/celite, a previously described technique for isolating plasminogen activators with a high fibrin affinity (S. Husain, B. Lipinski, and V. Gurewich, 1981, Proc. Nat. Acad. Sci. USA 78, 4265-4269), was performed on freshly voided urine. About 10-25% of the plasminogen activator activity present was adsorbed whereas less than 1% was adsorbed when urine was stored at room temperature for 12-24 h. The adsorbed activator was isolated by elution with arginine (0.1 M) and further purified by gel filtration. This plasminogen activator was similar in molecular weight (56,000) to the known high-molecular-weight form of urokinase but differed from it by its binding affinity for fibrin/celite, single-chain subunit structure, lower specific activity (approximately 20,000 IU/mg), and slower reaction with diisopropylfluorophosphate. The enzymatic activity of the purified activator was quenched by anti-urokinase antibody and therefore established it to be a new form of urokinase. The relationship of this high affinity, single-chain urokinase to the previously described forms of urokinase is unclear.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338833     DOI: 10.1016/0003-9861(83)90383-1

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  11 in total

1.  Human endothelial cell line, ECV304, produces pro-urokinase.

Authors:  K Takahashi; Y Sawasaki
Journal:  In Vitro Cell Dev Biol       Date:  1991-10

2.  Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.

Authors:  R Pannell; J Black; V Gurewich
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

3.  Purification and characterization of fibrinolytic enzyme from a bacterium isolated from soil.

Authors:  Xiong Xin; Ranga Rao Ambati; Zongwei Cai; Bo Lei
Journal:  3 Biotech       Date:  2018-01-23       Impact factor: 2.406

4.  Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.

Authors:  V Gurewich; R Pannell; S Louie; P Kelley; R L Suddith; R Greenlee
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  Purification and biochemical characterization of a 17 kDa fibrinolytic enzyme from Schizophyllum commune.

Authors:  In Suk Park; Jeong Uck Park; Min Jeong Seo; Min Jeong Kim; Hye Hyeon Lee; Sung Ryeal Kim; Byoung Won Kang; Yung Hyun Choi; Woo Hong Joo; Yong Kee Jeong
Journal:  J Microbiol       Date:  2011-01-09       Impact factor: 3.422

6.  Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator.

Authors:  A M Buko; E J Kentzer; A Petros; G Menon; E R Zuiderweg; V K Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

Review 7.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 8.  Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.

Authors:  J Loscalzo
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

9.  Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).

Authors:  V Gurewich; R Pannell; R J Broeze; J Mao
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

10.  Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.

Authors:  C Genton; E K Kruithof; W D Schleuning
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.